BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 28, 2004
 |  BioCentury  |  Strategy

Schering's newco

Schering AG's decision to spin out its dermatology group could create one of the largest biotech companies in Europe. But to make it happen, the to-be-named company will need to bolster its clinical pipeline and expand its marketing capabilities.

Indeed, the new company is still in the process of being formed. Although he has yet to be appointed, Wolfgang Kehr told BioCentury that he will be CEO. Kehr is managing director of the center for dermatology at Schering (FSE:SCH; SHR, Berlin, Germany).

"The goal is to create a fully fledged pharmaceutical company, but it will initially have the attitude of a biotech company," Kehr said. "We want to create the spirit of a biotech company and give employees the feeling that they have ownership in the...

Read the full 618 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >